CSI Market
Sign In | Register

Royalty Pharma Plc (RPRX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access RPRX Annual Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Royalty Pharma Plc funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income1,260.48
Depreciation & amortization2.47
Amortization of Other Assets11.52
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges69.44
Provision For Loan Losses Expensed70.73
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation229.65
Proceeds from Equity Method Investment, Dividends or Distributions50.57
Fair Value Adjustment of Warrants0.00
Gains Losses On Sales Of Assets915.60
Impairment Of Intangible Assets Excluding Goodwill3.77
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities3.06
Accrued Expense-3.05
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.00
Other Working Capital1.96
Other Noncash Income (Expense)-5.31
Other net237.17
Payments for (Proceeds from) Other Operating Activities-482.00
Discontinued operations0.00
Net Cash flow from Operating Activities1,446.69
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale of Available-for-sale Securities, Debt8.64
Payments to Acquire Available-for-sale Securities, Debt0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Proceeds from Equity Method Investment, Dividends or Distributions, Return of Capital29.09
Sale of businesses0.00
Accounts payable0.00
Payments to Acquire Finance Receivables-703.39
Payments for (Proceeds from) Other Investing Activities-0.32
Other Net-41.62
Discontinued operations0.00
Net Cash Flow from Investing Activities-707.59
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-2.46
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-94.74
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock-74.48
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-0.62
Other net-373.53
Proceeds From Issuance Of Common Stock And Warrants Net-
Proceeds From Stock Options And Warrants Exercises-
Proceeds From Issuance Of Common Stock And Warrants-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-545.82
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow1,446.69
Total Cash Flow193.29
4 historic quarters locked

Sign in to unlock the full Royalty Pharma Plc cash flow history.

Sign In Create Free Account

About Royalty Pharma Plc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001802768-26-000015

Figures are derived from filed reports and may be restated. Historical data is subject to revision.